about
Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer MetastasisTargeting ECM Disrupts Cancer ProgressionRecapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture ModelsDefining the extracellular matrix using proteomicsStromal characteristics may hold the key to mammographic density: the evidence to dateMolecular Cues Guiding Matrix Stiffness in Liver FibrosisThe Extracellular Matrix in Epithelial Ovarian Cancer - A Piece of a Puzzle.Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases.Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.Opening the LOX to bone metastasis: The role of secreted lysyl oxidase in skeletal recurrence of breast cancers.Reorganized Collagen in the Tumor Microenvironment of Gastric Cancer and Its Association with Prognosis.Association of the G473A polymorphism and expression of lysyl oxidase with breast cancer risk and survival in European women: a hospital-based case-control studyLOXL2 in epithelial cell plasticity and tumor progression.Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.Reactive oxygen species in normal and tumor stem cells.Structural ECM components in the premetastatic and metastatic niche.P190B RhoGAP overexpression in the developing mammary epithelium induces TGFβ-dependent fibroblast activationHypoxia and the extracellular matrix: drivers of tumour metastasisPARVA promotes metastasis by modulating ILK signalling pathway in lung adenocarcinomaLysyl hydroxylase 2 induces a collagen cross-link switch in tumor stromaLysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression.Targeting lysyl oxidase for molecular imaging in breast cancer.Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma.Inhibition of BMP signaling suppresses metastasis in mammary cancerTumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma.Advances in biophotonics detection of field carcinogenesis for colon cancer risk stratification.Insight On Colorectal Carcinoma Infiltration by Studying Perilesional Extracellular Matrix.Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition.Heparanase 2 Attenuates Head and Neck Tumor Vascularity and Growth.Enzymatic and non-enzymatic functions of the lysyl oxidase family in boneLOXL4 is induced by transforming growth factor β1 through Smad and JunB/Fra2 and contributes to vascular matrix remodeling.The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase.Ultrastructural alterations in field carcinogenesis measured by enhanced backscattering spectroscopy.The effect of LOXL2 in hepatocellular carcinoma.Heparanase 2 expression inversely correlates with bladder carcinoma grade and stage.Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer.Low extracellular lysyl oxidase expression is associated with poor prognosis in patients with prostate cancer.P-selectin-mediated LOX expression promotes insulinoma growth in Rip1-Tag2 mice by increasing tissue stiffness
P2860
Q26767150-D86292F0-409F-4164-BF46-04E0BB9D124BQ26779300-1610C2F6-3AC3-40CE-924F-F50AA2DAF99EQ26797285-2F6A5F88-29AB-4A1E-98C6-28E1F424E49AQ26830221-A00314B6-FBE0-4C70-8A6A-74D48C5B52F3Q28066162-6DD6DB7E-7E1F-4FF3-9362-523CC2DDDC60Q28077583-DFA7B5CC-CBF8-483D-B84C-051CDEC3FDF0Q33361929-C16819FD-EABC-4CB3-A94D-20B06153E206Q33628057-51115F7B-E12C-4524-ACF1-1221BAD9EB4CQ33688524-EFAB1243-2544-4FA1-A50E-2255244CEFABQ33704134-87A441F9-0752-43D5-B36A-7480CFEE265CQ33820881-081A6979-045C-41E7-98C6-8874EDEA54CFQ34070903-F433F301-3969-4DC1-9843-024460E9DB3DQ34303455-04F65FDE-8971-4EA2-889E-F353D029839DQ34371559-2BAE4F30-D0B7-4A04-A8CE-D6A9935D2E75Q34392752-5F285208-9555-40F9-BF8E-068F92F53506Q34521147-35C7BB97-7EC1-4D3A-B952-8D0FCE28261EQ34746645-8AE6E914-110B-4D3B-8108-DECD161B9A6FQ34820282-531CFA3A-1B13-4464-8A6A-2F9CD90ABDAFQ35147563-ABE3E74F-44D1-4CD6-8D6D-FD49B09CF205Q35183870-3A62F734-8869-47FF-BFFE-A8352C09CE46Q35527142-EBE0FDB6-34E6-40FD-89DE-72127B599A13Q35945328-61471B38-FC81-4991-A723-4487E4D80BB6Q36000813-FCEF96D6-4070-4321-B593-B03B0C132F0EQ36059910-F829CD43-0D43-4C56-99CB-00CECE983B64Q36398681-739BB690-EECC-4BFB-8296-8EB63CC8A45DQ36498118-416B0D29-E801-4481-AECB-E3B1FF790EA9Q36646557-8F0C6FF8-708A-4160-9B07-F916807CE3A2Q36650869-A3E2A7C2-E8A9-4AAA-8428-36BC7CB05D9FQ36736295-977AE6C9-7129-4681-A50C-D6FC88ECEEEFQ36917969-A3BA0EC3-C46F-463A-BF3A-00B14614649CQ36923574-C07BCF38-06ED-4416-AC3F-3967336171BEQ36978251-B2275F74-CCA7-4D22-A32C-482982CB42CDQ37126990-AD5208DA-2D67-4628-8108-1709C5E9D09BQ37149996-8A28DAEB-FB14-40FD-B8BE-FE27F7DCEF98Q37190899-458B812D-961F-4316-8ABA-9CD5CD35FD66Q37225598-11773B2E-AD64-4C91-898D-06F2F5AEC3E9Q37311904-CFB0913D-9CED-4BEE-A06C-F20D2ED92521Q37326797-8C17DECE-DE9E-4B9E-A2C0-CD8B29684656Q37406845-A03DB6E3-5AAD-47CE-B8EE-E2594E98D61CQ37428159-A528BA8A-EDD5-4C39-93FF-180BB75CFF3B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The rationale for targeting the LOX family in cancer.
@en
type
label
The rationale for targeting the LOX family in cancer.
@en
prefLabel
The rationale for targeting the LOX family in cancer.
@en
P356
P1476
The rationale for targeting the LOX family in cancer.
@en
P2093
Holly E Barker
P2888
P304
P356
10.1038/NRC3319
P407
P577
2012-07-19T00:00:00Z
P5875
P6179
1014871876